Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Anocca has achieved regulatory approval for its first clinical trial, VIDAR-1, a major milestone in the company’s transition ...

CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

An extensive tumor genomic analysis of individuals with ovarian cancer, led by researchers from Huntsman Cancer Institute at ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations.

A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have uncovered a powerful combination therapy leveraging sotorasib-an FDA-approved ...